MAZE
Maze Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-7/100
Last price
26.43
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
26.43
Day high
26.82
Day low
25.79
Volume
682.83K
Market cap
$1.47B
P/E (TTM)
—
52W range
21.95 – 53.65
Trailing performance
Returnvs SPY
1W
-2.18%
-4.1%
1M
+0.84%
-0.3%
3M
-17.38%
-21.9%
6M
-6.71%
-24.9%
YTD
-36.21%
-50.5%
1Y
-2.51%
-18.9%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MAZE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-110.34K
Net selling
Buy transactions
16
236.97K shares
Sell transactions
23
347.32K shares
Net transactions
+39
Buys less sells
Sell : buy shares
1.5 : 1
Mixed
Insider-held shares
850.46K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | DANDEKAR ATUL Officer |
SELL | 7.50K | $202.92K | Direct |
| Sep 29, 26 | DANDEKAR ATUL Officer |
CONVERSION | 7.50K | $78.15K | Direct |
| Sep 4, 26 | BERNSTEIN HAROLD Officer |
SELL | 9.71K | $254.50K | Direct |
| Sep 3, 26 | COLOMA JASON V PH.D. Chief Executive Officer |
SELL | 22.64K | $593.96K | Direct |
| Sep 3, 26 | COURTNEY PHILLIPS General Counsel |
SELL | 3.99K | $104.77K | Direct |
| Sep 3, 26 | BERNSTEIN HAROLD Officer |
SELL | 10.29K | $270.11K | Direct |
| Sep 3, 26 | DANDEKAR ATUL Officer |
SELL | 6.43K | $168.81K | Direct |
| Sep 1, 26 | COLOMA JASON V PH.D. Chief Executive Officer |
SELL | 34.50K | $907.00K | Indirect |
| Sep 1, 26 | BERNSTEIN HAROLD Officer |
SELL | 16.14K | $425.51K | Direct |
| Sep 1, 26 | COLOMA JASON V PH.D. Chief Executive Officer |
— | 50.00K | — | Direct |
| Sep 1, 26 | COURTNEY PHILLIPS General Counsel |
— | 11.00K | — | Direct |
| Sep 1, 26 | BERNSTEIN HAROLD Officer |
CONVERSION | 36.14K | $168.19K | Direct |
| Sep 1, 26 | DANDEKAR ATUL Officer |
— | 12.50K | — | Direct |
| Aug 28, 26 | DANDEKAR ATUL Officer |
SELL | 7.50K | $206.82K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BACHRODT AMY |
Officer | 12.96K | Sale |
BERNSTEIN HAROLD |
Officer | 0 | Sale |
COLOMA JASON V PH.D. |
Chief Executive Officer | 268.87K | Sale |
COURTNEY PHILLIPS |
General Counsel | 7.01K | Sale |
DANDEKAR ATUL |
Officer | 32.32K | Sale |
HOMCY CHARLES J |
Director | 31.11K | Stock Gift |
LIM JONATHAN E |
Director | — | Conversion of Exercise of derivative security |
SCHELLER RICHARD H |
Director | 0 | Sale |
SOHN CATHERINE A |
Director | 0 | Sale |
THIRD ROCK VENTURES IV, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.47B
Enterprise value$1.12B
Revenue (TTM)$20.00M
Gross profit$20.00M
EBITDA$-143.71M
Net income$-133.59M
EPS (TTM)$-2.48
Free cash flow$-63.63M
Total cash$411.09M
Total debt$60.42M
Book value / share$8.16
Shares outstanding55.55M
Float36.80M
Short % of float11.51%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.20
PEG ratio—
Price / sales—
Price / book3.24
EV / revenue55.88
EV / EBITDA-7.78
Gross margin100.00%
Operating margin-728.06%
Profit margin0.00%
Return on equity-37.35%
Return on assets-21.79%
Debt / equity13.34
Current ratio18.31
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $167.50M | $0 | $0 | -100.0% |
| Operating revenue | $0 | $167.50M | $0 | $0 | -100.0% |
| Research & development | $108.45M | $83.50M | $73.94M | $88.19M | +29.9% |
| Selling, general & admin | $34.45M | $26.42M | $24.61M | $22.83M | +30.4% |
| Total operating expense | $142.90M | $109.91M | $98.55M | $111.03M | +30.0% |
| Operating income | -$142.90M | $57.59M | -$98.55M | -$111.03M | -348.1% |
| Net interest income | $11.78M | $4.65M | $1.97M | $2.03M | +153.1% |
| Pre-tax income | -$131.12M | $53.40M | -$100.42M | -$114.94M | -345.5% |
| Tax provision | $0 | $1.17M | $0 | — | -100.0% |
| Net income | -$131.12M | $52.23M | -$100.42M | -$114.94M | -351.0% |
| Net income to common | -$131.12M | $3.40M | -$100.42M | -$114.94M | -3,950.8% |
| Basic EPS | -3.05 | 0.08 | -2.87 | -3.29 | -4,021.3% |
| Diluted EPS | -3.05 | 0.08 | -2.87 | -3.29 | -4,021.3% |
| EBIT | -$142.90M | $57.59M | -$98.55M | -$111.03M | -348.1% |
| EBITDA | -$140.50M | $60.88M | -$94.46M | -$107.21M | -330.8% |
| Basic shares | 42.98M | 43.78M | 34.97M | 34.97M | -1.8% |
| Diluted shares | 42.98M | 43.78M | 35.40M | 35.40M | -1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $189.25M | $196.81M | $29.16M | $99.92M | -3.8% |
| Cash & short-term investments | $341.92M | $196.81M | $29.16M | $99.92M | +73.7% |
| Total current assets | $349.72M | $201.67M | $34.11M | $106.15M | +73.4% |
| Property, plant & equipment | $25.16M | $29.92M | $34.98M | $41.23M | -15.9% |
| Total assets | $397.13M | $240.54M | $71.50M | $149.96M | +65.1% |
| Total current liabilities | $22.56M | $20.67M | $16.32M | $20.78M | +9.1% |
| Long-term debt | — | — | $20.08M | — | — |
| Total debt | $23.31M | $26.63M | $49.62M | $32.05M | -12.5% |
| Total liabilities | $42.16M | $551.73M | $445.35M | $432.42M | -92.4% |
| Retained earnings | -$489.55M | -$358.43M | -$395.69M | -$295.27M | -36.6% |
| Shareholder equity | $354.97M | -$311.18M | -$373.85M | -$282.46M | +214.1% |
| Working capital | $327.16M | $181.00M | $17.79M | $85.37M | +80.8% |
| Net tangible assets | $354.97M | -$311.18M | -$373.85M | -$282.46M | +214.1% |
| Shares issued | 49.34M | 43.78M | 43.78M | 43.78M | +12.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$131.12M | $52.23M | -$100.42M | -$114.94M | -351.0% |
| Depreciation & amortisation | $2.40M | $3.30M | $4.09M | $3.82M | -27.1% |
| Stock-based compensation | $16.40M | $9.65M | $8.75M | $6.74M | +70.0% |
| Change in working capital | -$2.27M | -$1.52M | -$6.32M | -$3.24M | -49.2% |
| Operating cash flow | -$111.94M | $75.95M | -$86.83M | -$99.20M | -247.4% |
| Capital expenditure | -$794.00K | -$1.15M | -$441.00K | -$1.97M | +30.8% |
| Investing cash flow | -$170.96M | -$1.15M | -$441.00K | -$3.17M | -14,805.1% |
| Financing cash flow | $275.34M | $92.85M | $16.39M | $1.73M | +196.5% |
| Free cash flow | -$112.73M | $74.81M | -$87.27M | -$101.17M | -250.7% |
| End cash position | $190.34M | $197.90M | $30.25M | $101.13M | -3.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $20.00M | $0 | $0 | $0 | -100.0% |
| Operating revenue | $0 | $20.00M | $0 | $0 | $0 | -100.0% |
| Research & development | $34.94M | $34.15M | $27.57M | $25.19M | $28.11M | +2.3% |
| Selling, general & admin | $13.10M | $12.40M | $10.49M | $7.78M | $8.37M | +5.6% |
| Total operating expense | $48.03M | $46.55M | $38.06M | $32.97M | $36.47M | +3.2% |
| Operating income | -$48.03M | -$26.55M | -$38.06M | -$32.97M | -$36.47M | -80.9% |
| Net interest income | $3.31M | $2.35M | $3.49M | $2.88M | $2.79M | +41.1% |
| Pre-tax income | -$44.73M | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -84.8% |
| Tax provision | — | — | $0 | $0 | $0 | — |
| Net income | -$44.73M | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -84.8% |
| Net income to common | -$44.73M | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -84.8% |
| Basic EPS | -0.76 | -0.45 | -0.65 | -0.66 | -0.77 | -68.9% |
| Diluted EPS | -0.76 | -0.45 | -0.65 | -0.66 | -0.77 | -68.9% |
| EBIT | -$43.80M | -$23.34M | -$38.06M | -$32.97M | -$33.68M | -87.6% |
| EBITDA | -$43.41M | -$22.90M | -$37.56M | -$32.39M | -$33.03M | -89.6% |
| Basic shares | 59.00M | 53.90M | 53.40M | 45.78M | 43.80M | +9.5% |
| Diluted shares | 59.00M | 53.90M | 53.40M | 45.78M | 43.80M | +9.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $202.64M | $198.77M | $189.25M | $316.77M | $264.54M | +2.0% |
| Cash & short-term investments | $411.09M | $352.38M | $341.92M | $383.94M | $264.54M | +16.7% |
| Accounts receivable | — | $20.00M | — | — | — | — |
| Total current assets | $420.42M | $379.78M | $349.72M | $391.30M | $271.15M | +10.7% |
| Property, plant & equipment | $22.83M | $23.97M | $25.16M | $26.46M | $27.71M | -4.7% |
| Total assets | $531.63M | $419.71M | $397.13M | $422.06M | $303.52M | +26.7% |
| Total current liabilities | $22.96M | $21.24M | $22.56M | $22.11M | $19.90M | +8.1% |
| Long-term debt | $38.96M | $38.83M | — | — | — | +0.3% |
| Total debt | $60.42M | $61.22M | $23.31M | $24.18M | $25.01M | -1.3% |
| Total liabilities | $78.50M | $78.01M | $42.16M | $42.62M | $41.28M | +0.6% |
| Retained earnings | -$558.48M | -$513.75M | -$489.55M | -$454.98M | -$424.89M | -8.7% |
| Shareholder equity | $453.12M | $341.70M | $354.97M | $379.44M | $262.24M | +32.6% |
| Working capital | $397.46M | $358.54M | $327.16M | $369.19M | $251.25M | +10.9% |
| Net tangible assets | $453.12M | $341.70M | $354.97M | $379.44M | $262.24M | +32.6% |
| Shares issued | 55.50M | 49.74M | 49.34M | 48.08M | 43.85M | +11.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$44.73M | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -84.8% |
| Depreciation & amortisation | $391.00K | $444.00K | $499.00K | $571.00K | $649.00K | -11.9% |
| Stock-based compensation | $9.19M | $7.11M | $6.07M | $3.86M | $3.24M | +29.2% |
| Change in working capital | $19.12M | -$23.68M | -$311.00K | $501.00K | -$1.04M | +180.8% |
| Operating cash flow | -$15.05M | -$39.11M | -$27.73M | -$24.64M | -$30.05M | +61.5% |
| Capital expenditure | -$107.00K | -$93.00K | -$34.00K | -$68.00K | -$393.00K | -15.1% |
| Investing cash flow | -$128.51M | $6.28M | -$103.39M | -$66.88M | -$393.00K | -2,147.9% |
| Financing cash flow | $147.44M | $42.36M | $3.59M | $143.76M | $612.00K | +248.1% |
| Free cash flow | -$15.16M | -$39.21M | -$27.76M | -$24.71M | -$30.45M | +61.3% |
| End cash position | $203.73M | $199.85M | $190.34M | $317.86M | $265.63M | +1.9% |
Options analytics
Put / call volume
0.31
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
15.00
-43.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
13
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
35.00
1 contracts
Heaviest put OI
22.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.70 | -0.76 | -9.2% |
| Mar 2026 | -0.62 | — | — |
| Dec 2025 | -0.69 | -0.65 | +5.7% |
| Sep 2025 | -0.69 | -0.66 | +4.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.75 | 9 | $0 | 0.0% |
| Next quarter | -0.79 | 9 | $0 | 0.0% |
| Current year | -2.74 | 9 | $20.00M | 0.0% |
| Next year | -3.22 | 9 | $8.11M | -59.5% |
Analyst targets & ownership
Mean target$61.50
High target$110.00
Low target$46.00
Implied upside132.69%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy1 / 12
Hold0
Sell / Strong sell0 / 0
Held by insiders1.53%
Held by institutions106.87%
Institutions holding227
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
26.73
-1.14% from price
SMA 20
25.54
+3.47% from price
SMA 50
26.93
-1.86% from price
SMA 100
27.00
-2.10% from price
SMA 200
32.86
-19.56% from price
EMA 12
26.33
+0.38% from price
EMA 26
26.34
+0.35% from price
EMA 50
26.76
-1.25% from price
RSI (14)
50.5
Neutral
MACD (12,26,9)
-0.01
Hist 0.20
ATR (14)
2.02
7.63% of price
Realised vol 30D
80.2%
Annualised
Bollinger upper
28.90
20, 2σ
Bollinger lower
22.19
20, 2σ
50 / 200 cross
Death
26.93 vs 32.86
Trend bias
Below 200
-19.56%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.77
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
80.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-56.8%
Peak to trough
Max drawdown 5Y
-56.8%
Peak to trough
ATR 14
2.02
7.63% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
5.68M
Prior 5.99M
Change vs prior
-5.2%
Shorts covering
% of float
11.51%
Elevated
% of shares out
10.22%
Against total outstanding
Days to cover
12.3
Crowded exit
Float
36.80M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 23, 26 | Citigroup | INITIATED | — | Buy |
| Sep 23, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 22, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 12, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Mar 31, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Mar 25, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 18, 26 | Truist Securities | INITIATED | — | Buy |
| Mar 16, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 10, 26 | Mizuho | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-17
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-12
Annual Report to Shareholders
ARS · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-04-22
Corporate Changes & Voting Matters
8-K · 2026-03-25
Headlines
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
GlobeNewswire · 15h ago
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
MarketBeat · 2d ago
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
Insider Monkey · 8d ago
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Simply Wall St. · 12d ago
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
InvestorsHub · 14d ago
Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
MT Newswires · 14d ago
BTIG Initiates Maze Therapeutics at Buy With $50 Price Target
MT Newswires · 14d ago
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Investor's Business Daily · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.